2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Apoptosis, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

1785 Survival outcomes and excess mortality in Waldenström macroglobulinemia relative to the United States general population across treatment eras

Muhammad Azeem Khan, MBBS, Gunjan Gaur, MD2, Jithma Abeykoon, MD3, Jonas Paludo, MD4, Morie Gertz, MD5, Shaji Kumar, MD6, Rebecca L King, MD7, Thomas M. Habermann, MD8, Ronald Go, MD9, Joselle M Cook, M.D.10, Nadine Abdallah I, MD11, Gita Thanarajasingam, MD12, Francis Buadi, MD13, Angela Dispenzieri, MD14, Carrie Thompson, MD15, Wilson Gonsalves, MD16, Grzegorz Nowakowski, MD17, David Dingli, MD, PhD18, Eli Muchtar, MD19, Patricia Greipp, DO20, Surendra Dasari, Associate Professor21, Joseph Peter Novak, MS22, Rahma Warsame, MD23, Thomas Witzig, MD24, S. Vincent Rajkumar, MD25, Stephen Maxted Ansell, MD, PhD26, Prashant Kapoor, MD27, Saurabh Zanwar, MBBS, MD28
1 Mayo Clinic, Rochester, United States
2 Mayo Clinic, Rochester, United States
3 Mayo Clinic, Rochester, United States
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 Mayo Clinic, Rochester, United States
9 Mayo Clinic, Rochester, United States
10 Mayo Clinic, Rochester, United States
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Mayo Clinic, Rochester, United States
16 Mayo Clinic, Rochester, United States
17 Mayo Clinic, Rochester, United States
18 Mayo Clinic, Rochester, United States
19 Mayo Clinic, Rochester, United States
20 Mayo Clinic, Rochester, United States
21 Mayo Clinic, Rochester, United States
22 Mayo Clinic, Rochester, United States
23 Mayo Clinic, Rochester, United States
24 Mayo Clinic, Rochester, United States
25 Mayo Clinic, Rochester, United States
26 Mayo Clinic, Rochester, United States
27 Mayo Clinic, Rochester, United States
28 Mayo Clinic, Rochester, United States

Background: Therapeutic advances have transformed the management of Waldenström macroglobulinemia (WM), resulting in improved disease control. However, interpretation of overall survival (OS) remains challenging because WM primarily affects older adults who are at increased risk of non–WM-related mortality. Consequently, the degree to which survival among patients with WM has approached that of the general U.S. population is unknown. We evaluated temporal trends in survival and assessed excess mortality relative to an age-, sex-, and calendar year–matched U.S. population. 

Methods: We performed a retrospective single-center study of 1,020 consecutive patients with active WM diagnosed between 1996 and 2018. Patients were stratified into two treatment eras based on the year of active disease diagnosis (1996–2005 vs. post-2006), corresponding to major advances in WM therapy. OS and cause-specific survival (CSS) were estimated using Kaplan–Meier methods. Competing risk analyses evaluated WM-related mortality while accounting for non–WM-related deaths. Excess mortality relative to the U.S. general population was assessed using standardized mortality ratios (SMRs) derived from Human Mortality Database life tables (www.mortality.org;data accessed March 4, 2026) matched for age, sex, and calendar year.

Results: The cohort had a median age of 66.2 years and a median follow-up of 13.1 years. Although therapeutic strategies evolved substantially over time, including increased rituximab use and the introduction of BTKi therapy, OS for the overall cohort did not differ significantly across treatment eras (median 10.9 vs. 11.9 years, P=0.64). Among patients younger than 65 years, however, OS improved significantly in the post-2006 era, increasing from 14.1 to 18.8 years (P=0.018), whereas no significant improvement was observed among patients aged ≥65 years.

In contrast, WM-specific outcomes improved consistently across successive treatment eras. Median CSS increased from 15.6 years in patients diagnosed during 1996–2005 to 18.9 years in those diagnosed after 2006 (p<0.0001); 10-year CSS improved from 65.4% to 77.7%. Competing risk analyses confirmed a significant reduction in WM-related mortality over time, with the 10-year cumulative incidence of WM-specific death decreasing from 32.4% (95% CI 28.9–38.1%) to 21.5% (95% CI 18.8–24.5%) in the two-era analysis (P<0.001).

Despite these encouraging improvements, patients with WM continued to experience substantially higher mortality than the matched U.S. general population. Overall excess mortality declined modestly across treatment eras (SMR 1.99 vs. 1.75), but remained significantly elevated. Notably, younger patients experienced the greatest relative excess mortality, with an SMR of 2.79 (95% CI, 2.41–3.21; P<0.001), indicating nearly a threefold higher risk of death compared with similarly aged individuals in the general population. In contrast, patients aged ≥65 years had a lower, though still significantly elevated, SMR of 1.57 (95% CI, 1.40–1.73; P<0.001).

Conclusions: Modern therapies have significantly reduced WM-related mortality and substantially improved cause-specific survival across successive treatment eras. However, patients with WM continue to experience significantly higher mortality than the age-, sex-, and calendar year–matched U.S. population, particularly among those diagnosed before age 65. These findings highlight that, despite therapeutic advances, a considerable survival gap persists and underscore the continued need for more effective treatment strategies capable of normalizing life expectancy in patients with WM.

Muhammad Azeem Khan, MBBS: No relevant conflicts of interest to declare.